RPS20 Antibody

What is RPS20 and what are its cellular functions?

RPS20 is a component of the 40S ribosomal subunit, functioning as a 119 amino acid cytoplasmic protein that belongs to the universal ribosomal protein uS10 family. While its primary role involves participation in protein synthesis as part of the ribosomal machinery, recent research has uncovered additional non-canonical functions. Studies indicate that RPS20 may influence cell proliferation, migration, and invasion in certain cancers, particularly renal clear cell carcinoma (KIRC) . Its expression has been shown to impact the regulation of cell cycle mediators like CDK4 and cyclin D1, as well as epithelial-mesenchymal transition markers including E-cadherin and N-cadherin . Furthermore, RPS20 appears to modulate important signaling pathways, such as the ERK-MAPK and AKT-mTOR cascades, suggesting broader roles beyond protein synthesis .

What applications are RPS20 antibodies validated for?

RPS20 antibodies have been validated for multiple experimental applications with specific recommended dilutions:

These applications enable researchers to detect endogenous levels of RPS20 protein across various experimental systems . When planning experiments, it's essential to follow manufacturer-recommended protocols while optimizing conditions for specific experimental systems.

What species reactivity do commercial RPS20 antibodies exhibit?

Most commercially available RPS20 antibodies demonstrate reactivity with human, mouse, and rat samples due to the high conservation of ribosomal proteins across species . Some antibodies show extended cross-reactivity with additional mammalian species:

• Human (primary reactivity found in almost all commercial antibodies)

• Mouse (commonly validated reactivity)

• Rat (commonly validated reactivity)

• Cow/bovine (select antibodies)

• Pig/porcine (select antibodies)

When working with less common model organisms, sequence homology analysis in the epitope region can help predict antibody compatibility. Preliminary validation experiments should confirm reactivity before proceeding with full-scale studies .

How should I choose the appropriate RPS20 antibody for my research?

Selecting the optimal RPS20 antibody requires consideration of several critical factors:

• Application compatibility: Verify validation data for your specific application (WB, IHC, IF, ELISA) . Not all antibodies perform equally across different techniques.

• Species reactivity: Confirm the antibody recognizes RPS20 in your species of interest through validation data or sequence homology analysis .

• Clonality: Choose between monoclonal (higher specificity, single epitope recognition) and polyclonal (multiple epitope recognition, potentially higher sensitivity) based on experimental requirements .

• Epitope specificity: Consider antibodies targeting specific regions (internal region, AA 1-119, AA 31-80) based on accessibility in your experimental system and potential post-translational modifications .

• Validation evidence: Review available data including Western blot images, IHC/IF staining patterns, and published literature using the antibody .

• Format requirements: Determine whether unconjugated or conjugated antibodies better suit your protocol .

For critical experiments, testing multiple antibodies targeting different epitopes can provide validation through consistent results.

How can I validate the specificity of an RPS20 antibody?

Rigorous validation of RPS20 antibody specificity is essential for generating reliable data. A comprehensive validation approach includes:

• Genetic manipulation controls:

  • Perform siRNA knockdown or CRISPR-Cas9 knockout of RPS20

  • Compare antibody signal between wild-type and knockdown samples

  • Signal reduction in knockdown samples confirms specificity

• Peptide competition assay:

  • Pre-incubate the antibody with excess immunizing peptide

  • Apply to duplicate samples alongside untreated antibody

  • Signal disappearance in peptide-blocked samples indicates specificity

• Multiple antibody comparison:

  • Test antibodies targeting different RPS20 epitopes

  • Consistent patterns increase confidence in specificity

  • Compare monoclonal and polyclonal antibodies when possible

• Mass spectrometry validation:

  • Immunoprecipitate RPS20 using the antibody

  • Confirm target identity through mass spectrometry

  • Identifies both target and potential cross-reactive proteins

• Western blot analysis:

  • Verify single band detection at the expected molecular weight (~13.4 kDa)

  • Include positive controls (tissues known to express RPS20)

  • Compare with recombinant RPS20 protein as reference standard

Commercial antibodies often undergo validation testing including Western blot, immunohistochemistry, and immunofluorescence against known positive controls, which provides a starting point for further validation in your specific experimental system .

What are the optimal conditions for immunohistochemistry with RPS20 antibodies?

Successful immunohistochemistry (IHC) with RPS20 antibodies requires attention to several critical parameters:

• Tissue preparation:

  • Fixation: 10% neutral buffered formalin for 24-48 hours

  • Processing: Standard paraffin embedding protocols

  • Sectioning: 4-5 μm thickness for optimal antibody penetration

• Antigen retrieval:

  • Heat-induced epitope retrieval (HIER) with pH 6 citrate buffer is recommended

  • Pressure cooker or microwave methods (20 minutes) typically provide sufficient retrieval

  • Allow sections to cool slowly to room temperature before antibody application

• Blocking and antibody incubation:

  • Blocking: 5-10% normal serum (from secondary antibody species) for 30-60 minutes

  • Primary antibody dilution: 1:100-1:500 depending on antibody sensitivity

  • Incubation: Overnight at 4°C or 1-2 hours at room temperature

  • Secondary detection: HRP-polymer or ABC method with DAB substrate

• Controls and interpretation:

  • Positive control: Human lymph node shows moderate cytoplasmic positivity in lymphoid cells

  • Negative control: Primary antibody omission

  • Expected pattern: Predominantly cytoplasmic staining

  • Quantification: Consider both staining intensity and percentage of positive cells

Optimization may be necessary for specific tissue types or experimental conditions. Standardizing these conditions across experiments enables reliable comparison of RPS20 expression between samples .

How should I design experiments to study RPS20's role in cancer progression?

When investigating RPS20's role in cancer progression, a comprehensive experimental approach should include:

• Expression analysis:

  • Compare RPS20 levels between matched tumor-normal tissues

  • Correlate expression with clinicopathological features (stage, grade, survival)

  • Use multiple detection methods (IHC, Western blot, qRT-PCR) for validation

  • Include a sufficient sample size with appropriate statistical analysis

• Functional studies:

  • Generate stable RPS20 knockdown and overexpression cell lines

  • Assess effects on:

    • Proliferation (MTT/CCK-8 assays, BrdU incorporation)

    • Migration (wound healing, transwell assays)

    • Invasion (Matrigel invasion assays)

    • Cell cycle progression (flow cytometry)

  • Examine both in vitro and in vivo models (xenograft experiments)

• Molecular mechanism investigation:

  • Analyze effects on key signaling pathways (ERK-MAPK, AKT-mTOR)

  • Assess expression of cell cycle regulators (CDK4, cyclin D1)

  • Examine EMT markers (E-cadherin, N-cadherin)

  • Perform rescue experiments to confirm specificity

• Clinical correlation:

  • Evaluate RPS20 as a prognostic biomarker using Kaplan-Meier analysis

  • Perform multivariate analysis to assess independent prognostic value

  • Consider combining with other markers for improved prognostic accuracy

Research on renal clear cell carcinoma has demonstrated that RPS20 knockdown suppresses proliferation, migration, and invasion, with corresponding effects on tumor formation in vivo . Similar experimental paradigms can be applied to investigate RPS20's role in other cancer types.

What controls are essential when studying RPS20 expression in tissue samples?

Robust controls are critical for reliable interpretation of RPS20 expression in tissue samples:

• Tissue controls:

  • Matched normal-tumor pairs from the same patient to control for genetic background

  • Progressive disease stages to establish correlation with disease advancement

  • Reference tissues with known RPS20 expression patterns

  • Tissue microarrays incorporating multiple stages/grades and normal controls

• Technical controls:

  • Antibody validation with positive and negative control tissues

  • Isotype control antibodies to assess non-specific binding

  • Peptide competition controls to confirm specificity

  • No primary antibody control to evaluate secondary antibody background

  • Internal positive controls (tissues known to express RPS20)

• Analytical controls:

  • Blinded evaluation by multiple observers

  • Standardized scoring system with clear criteria

  • Quantitative image analysis when possible

  • Inclusion of established prognostic markers for comparison

• Experimental design considerations:

  • Multiple detection methods (IHC, Western blot, qRT-PCR) for cross-validation

  • Batch processing of samples to minimize technical variation

  • Statistical controls for multiple comparisons

  • Independent validation cohort when possible

Research on renal clear cell carcinoma found that RPS20 expression correlated with tumor stage, differentiation grade, tumor size, and lymph node metastasis . Such correlations require comprehensive clinicopathological data collection and appropriate statistical analysis to identify potential confounding factors.

How can I use RPS20 antibodies in co-immunoprecipitation experiments?

Co-immunoprecipitation (Co-IP) with RPS20 antibodies requires careful optimization to preserve protein-protein interactions. Here's a methodological approach:

• Buffer optimization:

  • Use gentle lysis buffers to maintain protein complexes

  • Recommended buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate

  • Include protease and phosphatase inhibitors

  • Avoid harsh detergents like SDS that disrupt protein interactions

• Experimental procedure:

  • Pre-clear lysate with protein A/G beads to reduce non-specific binding

  • Incubate cleared lysate with RPS20 antibody (2-5 μg) overnight at 4°C

  • Add protein A/G beads and incubate for 1-4 hours

  • Wash beads 3-5 times with lysis buffer

  • Elute bound proteins with SDS sample buffer or by competition with immunizing peptide

• Critical controls:

  • Input control: Save a portion of pre-cleared lysate

  • IgG control: Parallel IP with isotype-matched non-specific IgG

  • Reverse IP: Immunoprecipitate with antibodies against suspected interaction partners

  • Validation: Confirm interactions by reciprocal Co-IP

• Special considerations for RPS20:

  • As a ribosomal protein, RPS20 may co-precipitate with other ribosomal components

  • RNase treatment can help distinguish RNA-dependent interactions

  • Crosslinking approaches may stabilize transient interactions

When investigating RPS20 interactions with signaling pathway components like those in the ERK-MAPK or AKT-mTOR pathways, these techniques can reveal the molecular mechanisms underlying RPS20's functions beyond protein synthesis .

What signaling pathways does RPS20 interact with or regulate?

Research indicates that RPS20 influences several important signaling pathways, particularly in cancer contexts:

• ERK-MAPK Pathway:

  • RPS20 appears to control activation of the ERK signaling pathway

  • RPS20 knockdown leads to reduced ERK pathway activation

  • This pathway regulates cell proliferation, differentiation, and survival

  • May represent a mechanism by which RPS20 influences cancer progression

• AKT-mTOR Pathway:

  • RPS20 modulates mTOR signaling activity

  • Studies show RPS20 increases cell proliferation by activating the AKT-mTOR axis

  • This pathway controls protein synthesis, cell growth, and metabolism

  • Particularly relevant given RPS20's role in translation machinery

• Cell Cycle Regulation:

  • RPS20 affects expression of cell cycle regulators

  • In RPS20 knockdown cell lines, CDK4 and cyclin D1 are downregulated

  • These proteins control G1/S phase transition, explaining proliferation effects

  • Provides mechanistic insight into RPS20's growth-promoting functions

• Epithelial-Mesenchymal Transition (EMT):

  • RPS20 knockdown alters expression of EMT markers

  • E-cadherin and N-cadherin expression changes with RPS20 modulation

  • EMT is critical for cancer invasion and metastasis

  • Suggests RPS20 may influence cancer cell phenotypic plasticity

These findings suggest RPS20 possesses important extra-ribosomal functions that contribute to cancer progression. Understanding these interactions provides potential therapeutic targets and insights into RPS20's role in disease processes .

How does RPS20 expression vary across different cancer types?

While research on RPS20 expression across cancer types is still emerging, several patterns have been identified:

• Renal Clear Cell Carcinoma (KIRC):

  • Significantly overexpressed in tumor tissues compared to corresponding normal tissues

  • Expression levels correlate with:

    • Tumor stage

    • Differentiation grade

    • Tumor size

    • Lymph node metastasis

  • Serves as an independent prognostic indicator

  • Associated with increased cell proliferation, migration, and invasion capabilities

• Potential mechanistic basis:

  • RPS20 overexpression appears to activate ERK-MAPK and AKT-mTOR signaling pathways

  • These pathways are fundamental drivers of cancer progression across multiple tumor types

  • RPS20 influences cell cycle regulators and EMT markers, which are universal cancer hallmarks

  • Suggests potential relevance in multiple cancer contexts beyond KIRC

To systematically compare RPS20 expression across cancer types, researchers can utilize public databases such as The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Human Protein Atlas, which provide both transcriptomic and proteomic data across tumor types. These resources enable identification of cancer-specific expression patterns and potential prognostic significance.

What approaches can I use to study RPS20 post-translational modifications?

Investigating post-translational modifications (PTMs) of RPS20 requires specialized techniques:

• Mass Spectrometry-Based Detection:

  • Immunoprecipitate RPS20 using validated antibodies

  • Perform tryptic digestion followed by LC-MS/MS analysis

  • Use bottom-up proteomics for modified peptide identification

  • Apply targeted approaches (parallel reaction monitoring) for quantification

  • Can identify phosphorylation, acetylation, methylation, ubiquitination and other modifications

• Gel-Based Approaches:

  • Phos-tag SDS-PAGE to detect phosphorylated forms

  • 2D gel electrophoresis to separate protein isoforms by charge and mass

  • Western blotting with modification-specific antibodies when available

  • Compare migration patterns before and after treatment with modification-removing enzymes

• Functional Analysis:

  • Generate modification-mimicking or modification-deficient mutants

  • Assess effects on:

    • Ribosome incorporation

    • Protein synthesis rates

    • Cellular localization

    • Protein-protein interactions

  • Compare wild-type and mutant RPS20 in rescue experiments

• Modification Dynamics:

  • Treat cells with stimuli affecting relevant signaling pathways

  • Monitor changes in RPS20 modifications over time

  • Assess effects of pathway inhibitors on modification status

  • Correlate with functional outcomes (proliferation, translation rates)

While ribosomal proteins including RPS20 are known to undergo various modifications that affect their function, the specific modification profile of RPS20 and its functional consequences remain areas requiring further investigation. These approaches provide a framework for characterizing this important regulatory layer.

How do I troubleshoot inconsistent RPS20 antibody staining patterns?

Inconsistent staining patterns with RPS20 antibodies can arise from multiple sources. Here's a systematic troubleshooting approach:

• Sample preparation issues:

  • Fixation variations: Standardize fixation protocols (time, temperature, concentration)

  • Processing inconsistencies: Process all samples simultaneously using identical protocols

  • Antigen retrieval: Optimize pH and heating conditions (HIER pH 6 recommended for RPS20)

  • Section thickness: Maintain consistent thickness (4-5 μm optimal)

• Antibody-related factors:

  • Antibody degradation: Aliquot antibodies; avoid freeze-thaw cycles; check expiration dates

  • Lot-to-lot variation: Validate each new lot against previous standards

  • Concentration inconsistency: Prepare larger volumes of working solution; use calibrated pipettes

  • Non-specific binding: Increase blocking time/concentration; optimize detergent concentrations

• Technical procedure variations:

  • Temperature fluctuations: Use temperature-controlled environments

  • Washing inconsistencies: Standardize washing steps (number, duration, agitation)

  • Incubation times: Maintain precise timing for all steps

  • Reagent application: Ensure complete and even coverage of sections

• Controls to implement:

  • Run positive and negative controls in parallel

  • Include isotype controls to identify non-specific binding

  • Use RPS20 knockdown cells as specificity controls

  • Compare results with orthogonal methods (Western blot, qPCR)

From the search results, RPS20 antibodies typically show cytosolic and endoplasmic reticulum localization in immunofluorescence applications . When troubleshooting, compare your observed patterns with expected localization to identify potential issues with specificity or technique .

What explains the observed molecular weight variations of RPS20 in Western blots?

Variations in RPS20's apparent molecular weight on Western blots can be attributed to several factors:

• Expected vs. observed molecular weight:

  • Calculated molecular weight of RPS20: ~13.4 kDa

  • Observed variations: Typically range from 12-20 kDa

• Post-translational modifications:

  • Phosphorylation adds ~80 Da per site

  • Ubiquitination adds ~8.5 kDa per ubiquitin

  • Methylation adds ~14 Da per methyl group

  • SUMOylation adds ~11 kDa per SUMO

• Technical factors affecting migration:

  • Gel percentage: Higher percentage gels (12-15%) improve resolution of small proteins

  • Running conditions: Voltage and temperature affect migration

  • Sample preparation: Denaturing conditions influence mobility

  • Buffer composition: Salt concentration affects protein-SDS interactions

• Experimental approaches to resolve variations:

  • Use gradient gels (4-20%) for better resolution

  • Include recombinant RPS20 as size reference

  • Perform sample treatments:

    • Phosphatase treatment to remove phosphorylation

    • Deubiquitinase treatment to remove ubiquitin

  • Compare multiple antibodies targeting different epitopes

Ribosomal proteins like RPS20 often undergo various modifications that can affect their electrophoretic mobility. When reporting Western blot results, specify the observed molecular weight, gel conditions, and any treatments that may affect protein mobility to facilitate comparison across studies .

How can I optimize immunofluorescence protocols for RPS20 antibodies?

Optimizing immunofluorescence (IF) for RPS20 antibodies requires attention to several key parameters:

• Sample preparation:

  • Fixation: 4% paraformaldehyde (10-15 minutes) preserves most epitopes

  • Permeabilization: 0.1-0.5% Triton X-100 (5-10 minutes) for cytoplasmic proteins like RPS20

  • From search results: "PFA/Triton X-100 fixation permeabilization" is specifically recommended

  • Blocking: 1-5% BSA or normal serum (30-60 minutes) to reduce background

• Antibody incubation:

  • Primary antibody dilution: 1:200-1:1000 (based on search results)

  • Incubation conditions: Overnight at 4°C or 1-2 hours at room temperature

  • Secondary antibody: Highly cross-adsorbed variants at 1:500-1:2000 dilution

  • Washing: PBS with 0.05-0.1% Tween-20 (3-5 washes of 5-10 minutes each)

• Image acquisition:

  • Counterstaining: DAPI for nuclear visualization

  • Mounting: Anti-fade medium to prevent photobleaching

  • Microscopy: Start with lower magnification to assess staining pattern

  • Confocal imaging for detailed subcellular localization

• Expected results and validation:

  • RPS20 typically shows cytosolic and endoplasmic reticulum localization

  • U-2 OS cells demonstrate good staining results according to validation data

  • Compare patterns with published localization data

  • Use RPS20 knockdown cells as negative controls

• Troubleshooting specific issues:

  • Weak signal: Increase antibody concentration or incubation time

  • High background: Enhance blocking or washing steps

  • Non-specific staining: Try different antibody clones or more stringent blocking

Optimizing each of these parameters systematically will help achieve specific and reproducible RPS20 immunofluorescence staining for accurate subcellular localization studies .

What statistical approaches are appropriate for analyzing RPS20 expression data?

Selecting appropriate statistical methods for RPS20 expression analysis depends on experimental design and data characteristics:

• Comparing expression between groups:

  • Student's t-test: For two-group comparison with normally distributed data

  • Mann-Whitney U test: Non-parametric alternative for non-normal distributions

  • ANOVA with post-hoc tests: For multiple group comparisons

  • Paired t-test or Wilcoxon signed-rank: For matched tumor-normal pairs

• Correlation and regression analysis:

  • Pearson correlation: For linear relationships between RPS20 and other markers

  • Spearman correlation: Non-parametric alternative for monotonic relationships

  • Multiple regression: To control for confounding variables

  • Logistic regression: For binary outcomes (e.g., metastasis presence)

• Survival analysis:

  • Kaplan-Meier method: Visualizing survival differences based on RPS20 expression

  • Log-rank test: Statistical comparison of survival curves

  • Cox proportional hazards: Multivariate survival analysis adjusting for covariates

  • Competing risks analysis: When multiple outcome events must be considered

• Data preprocessing considerations:

  • Normalization: Required for RNA-seq or microarray data

  • Multiple testing correction: Benjamini-Hochberg or Bonferroni when performing many comparisons

  • Outlier detection: Identify and address anomalous values

  • Batch effect correction: When combining data from multiple experiments

Based on published research, multivariate survival analysis was used to establish RPS20 as an independent prognostic factor in renal clear cell carcinoma, while correlation analysis associated RPS20 expression with clinical parameters including tumor stage, grade, size, and metastasis . When analyzing your own RPS20 expression data, consider both statistical significance and biological relevance, and report effect sizes alongside p-values for comprehensive interpretation.